Literature DB >> 15517606

Reconstitution of anti-HIV effector functions of primary human CD8 T lymphocytes by transfer of HIV-specific alphabeta TCR genes.

Takamasa Ueno1, Mamoru Fujiwara, Hiroko Tomiyama, Masafumi Onodera, Masafumi Takiguchi.   

Abstract

We redirected the antigen specificity of primary human CD8 T cells by retrovirus-mediated transduction of genes encoding alphabeta TCR specific to HIV-1 Pol protein. A large polyclonal population of TCR-transduced CD8 T cells showed substantial cytotoxic and cytokine production activities toward target cells either pulsed with the peptide or infected with HIV-1, and their functional activities were comparable to those of the parental CTL clone. Peptide fine-specificity and promiscuous recognition of HLA class I supertypes of the parental CTL clone were also preserved in the TCR-transduced cells. There were no signs of allogeneic responses in these cells, although hybrid TCR dimers consisting of transduced TCR and endogenous TCR were suspected to have been formed in these cells, as the effect of transgene expression on the surface expression of the desired TCR was limited. Moreover, the TCR-transduced cells showed potent inhibitory activity against HIV-1 replication in vitro, although the differential surface expression of the desired TCR resulted in differential functional avidity of individual TCR-transduced cells toward the peptide-pulsed target cells. These data suggest that the reconstitution of HIV-specific immunoreactive T cells engineered by genetic transfer of HIV-specific TCR is a potential alternative to immunotherapeutic applications against HIV infections.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517606     DOI: 10.1002/eji.200425568

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Protective capacity of virus-specific T cell receptor-transduced CD8 T cells in vivo.

Authors:  Katja Mueller; Anne von Mässenhausen; Ulrike Aichele; Lilian Stärck; Matthias Leisegang; Wolfgang Uckert; Hanspeter Pircher
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

2.  HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia/lymphoma.

Authors:  Benjy Jy Tan; Kenji Sugata; Omnia Reda; Misaki Matsuo; Kyosuke Uchiyama; Paola Miyazato; Vincent Hahaut; Makoto Yamagishi; Kaoru Uchimaru; Yutaka Suzuki; Takamasa Ueno; Hitoshi Suzushima; Hiroo Katsuya; Masahito Tokunaga; Yoshikazu Uchiyama; Hideaki Nakamura; Eisaburo Sueoka; Atae Utsunomiya; Masahiro Ono; Yorifumi Satou
Journal:  J Clin Invest       Date:  2021-12-15       Impact factor: 19.456

Review 3.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

Review 4.  Adoptive immunotherapy for cancer or viruses.

Authors:  Marcela V Maus; Joseph A Fraietta; Bruce L Levine; Michael Kalos; Yangbing Zhao; Carl H June
Journal:  Annu Rev Immunol       Date:  2014-01-09       Impact factor: 28.527

5.  Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.

Authors:  Aviva Joseph; Jian Hua Zheng; Antonia Follenzi; Teresa Dilorenzo; Kaori Sango; Jaime Hyman; Ken Chen; Alicja Piechocka-Trocha; Christian Brander; Erik Hooijberg; Dario A Vignali; Bruce D Walker; Harris Goldstein
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

6.  Transduction of SIV-specific TCR genes into rhesus macaque CD8+ T cells conveys the ability to suppress SIV replication.

Authors:  Eugene V Barsov; Matthew T Trivett; Jacob T Minang; Haosi Sun; Claes Ohlen; David E Ott
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

7.  A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.

Authors:  Hyun-Il Cho; Un-Hee Kim; A-Ri Shin; Ji-Na Won; Hyun-Joo Lee; Hyun-Jung Sohn; Tai-Gyu Kim
Journal:  Br J Cancer       Date:  2018-01-23       Impact factor: 7.640

Review 8.  Targeting cancers through TCR-peptide/MHC interactions.

Authors:  Qinghua He; Xianhan Jiang; Xinke Zhou; Jinsheng Weng
Journal:  J Hematol Oncol       Date:  2019-12-18       Impact factor: 17.388

9.  Clonotypically similar hybrid αβ T cell receptors can exhibit markedly different surface expression, antigen specificity and cross-reactivity.

Authors:  C Motozono; J S Bridgeman; D A Price; A K Sewell; T Ueno
Journal:  Clin Exp Immunol       Date:  2015-06       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.